Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc. (NTII) Revenue
Annual & quarterly revenue history · segment & region breakdown
NTII · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsNeurobiological Technologies, Inc. trailing twelve-month (TTM) revenue is $0.03B, an increase of 78.52% year-over-year from $0.03B in FY2009.
Revenue trend
2009 – 1994 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2009-06-30 | $0.03B | +$0.01B | +78.52% |
| 2008-06-30 | $0.01B | -$0.00B | -16.48% |
| 2007-06-30 | $0.02B | +$0.01B | +43.23% |
| 2006-06-30 | $0.01B | +$0.01B | +298.08% |
| 2005-06-30 | $0.00B | +$0.00B | +11.23% |
| 2004-06-30 | $0.00B | +$0.00B | +40.76% |
| 2003-06-30 | $0.00B | +$0.00B | — |
| 2002-06-30 | $0.00B | -$0.00B | -100.00% |
| 2001-06-30 | $0.00B | +$0.00B | +478124900.00% |
| 2000-06-30 | $0.00B | -$0.00B | -100.00% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Neurobiological Technologies, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Neurobiological Technologies, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Neurobiological Technologies, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NTII revenue · 4 questionsNTII's trailing twelve-month (TTM) revenue is $0.03B. That is an increase of 78.52% year-over-year from $0.03B in FY2009.
▸ Source: FMP · Neurobiological Technologies, Inc. SEC filings · GAAP · Neurobiological Technologies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026